Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share acquisition transactions.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details the acquisition of GSK Ordinary Shares by specific individuals on October 1, 2015, at a price of 1292.48 pence per Share. These acquisitions resulted from the reinvestment of dividends paid on Shares held through GSK's ShareReward Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is strictly administrative regarding director shareholdings.
Important Facts for Investors
- Transaction Type: Directors and PDMRs acquired shares via dividend reinvestment under the ShareReward Plan.
- Transaction Date: October 1, 2015.
- Share Price: 1292.48 pence per Share.
- Participants: Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr N Hirons, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Share Counts: Acquisitions ranged from 3 shares (Mr N Hirons) to 63 shares (Mr D S Redfern and Ms C Thomas).